Get the Stockscreener App
0.647
8.91%
0.052
Processa Pharmaceuticals Inc stock is traded at $0.647, with a volume of 94,401.
It is up +8.91% in the last 24 hours and down -31.79% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
See More
Previous Close:
$0.595
Open:
$0.611
24h Volume:
94,401
Relative Volume:
0.22
Market Cap:
$2.82M
Revenue:
-
Net Income/Loss:
$-11.53M
P/E Ratio:
-0.1342
EPS:
-4.82
Net Cash Flow:
$-11.12M
1W Performance:
-0.31%
1M Performance:
-31.79%
6M Performance:
-63.80%
1Y Performance:
-70.94%
1-Day Range:
$0.5772
$0.648
1-Week Range:
$0.5598
$0.682
52-Week Range:
$0.47
$3.305
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
7380 COCA COLA DRIVE, HANOVER
Compare PCSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.648 | 2.82M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.62 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.80 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.26 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.52 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.28 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference - GlobeNewswire
Processa Pharma's Cancer Pipeline Takes Center Stage at Elite BIO Investor Conference - StockTitan
Gastroparesis Market Expected to rise, 2034 | Vanda - openPR
Processa Pharmaceuticals CEO George Ng buys shares worth $69,542 - MSN
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Processa Pharmaceuticals Raises $5M in Public Offering - TipRanks
Processa CEO Doubles Down: Purchases Shares at 30% Premium in $5M Strategic Raise - StockTitan
Processa Pharmaceuticals director David Young buys $99,288 in stock - Investing.com India
Processa Pharmaceuticals' chief business officer buys $34,691 in stock - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Processa Pharmaceuticals' chief business officer buys $34,691 in stock By Investing.com - Investing.com South Africa
Processa Pharmaceuticals director David Young buys $99,288 in stock By Investing.com - Investing.com South Africa
Processa Pharmaceuticals CEO George Ng buys shares worth $69,542 By Investing.com - Investing.com UK
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Ulcerated Necrobiosis Lipoidica Market to Reach New Heights - openPR
Processa Pharmaceuticals stock hits 52-week low at $0.65 By Investing.com - Investing.com Canada
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
Processa CEO and Board Members Double Down: Major Insider Buying in Latest $5M Deal - StockTitan
Gastroparesis Drugs Market to Grow by USD 1.34 Billion (2025-2029), Driven by Rising Global Diabetes Burden, AI's Role in Market TransformationTechnavio - Yahoo Finance
PROCESSA PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K) -June 09, 2021 at 01:17 pm EDT - Marketscreener.com
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
Processa Pharmaceuticals stock hits 52-week low at $0.8 - MSN
Processa Pharmaceuticals stock hits 52-week low at $0.8 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 0.6% – Here’s Why - Defense World
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
Processa Pharmaceuticals stock hits 52-week low at $0.81 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals stock hits 52-week low at $0.81 - Investing.com
Gastroparesis Treatment Market Future Business Opportunities - openPR
Trump Media & Technology Group Corp (DJT-Q) QuotePress Release - The Globe and Mail
Gastroparesis Treatment Market Investment Opportunities: A Guide to 2031 | Evoke Pharma, Inc., Processa - EIN News
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
BCE Inc (BCE-T) QuotePress Release - The Globe and Mail
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
Processa Pharmaceuticals stock hits 52-week low at $0.85 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $0.85 - Investing.com
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics - The Globe and Mail
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
U S Antimony Corp (UAMY-A) QuotePress Release - The Globe and Mail
What is HC Wainwright’s Forecast for PCSA FY2024 Earnings? - Defense World
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer |
Jan 27 '25 |
Buy |
0.80 |
87,200 |
69,542 |
87,200 |
| Young David | Pres. Research & Development |
Jan 27 '25 |
Buy |
0.80 |
124,500 |
99,289 |
205,405 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 27 '25 |
Buy |
0.80 |
43,500 |
34,691 |
43,500 |
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):